NYMXF (Nymox Pharmaceutical) Current Accrued Expense : $4.31 Mil (As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Current Accrued Expense?

Nymox Pharmaceutical's Current Accrued Expense for the quarter that ended in Sep. 2024 was $4.31 Mil.

Nymox Pharmaceutical's quarterly Current Accrued Expense declined from Sep. 2023 ($2.56 Mil) to Dec. 2023 ($0.03 Mil) but then increased from Dec. 2023 ($0.03 Mil) to Sep. 2024 ($4.31 Mil).

Nymox Pharmaceutical's annual Current Accrued Expense declined from Dec. 2021 ($0.29 Mil) to Dec. 2022 ($0.24 Mil) and declined from Dec. 2022 ($0.24 Mil) to Dec. 2023 ($0.03 Mil).

Nymox Pharmaceutical Current Accrued Expense Historical Data

The historical data trend for Nymox Pharmaceutical's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Current Accrued Expense Chart

Nymox Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

0.27

0.32

0.29

0.24

0.03

Nymox Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Sep24
Current Accrued Expense	Get a 7-Day Free Trial															2.26	2.34	2.56	0.03	4.31

Nymox Pharmaceutical Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Nymox Pharmaceutical Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel